# Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

> **NCT01338870** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 301 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** 25 mg PF-04991532
- **DRUG:** 75 mg PF-04991532
- **DRUG:** 150 mg PF-04991532
- **DRUG:** 300 mg PF-04991532
- **DRUG:** Sitagliptin 100 mg

## Key facts

- **NCT ID:** NCT01338870
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2013-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338870, "Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01338870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*